Malta - engelsk - Medicines Authority

fresenius kabi limited - poly(o-2-hydroxyethyl)starch; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate; sodium chloride - solution for infusion - poly(o-2-hydroxyethyl)starch 60 g; potassium chloride 0.3 g; magnesium chloride hexahydrate 0.3 g; sodium acetate trihydrate 4.63 g; sodium chloride 6.02 g - blood substitutes and perfusion solutions

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 200 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

USA - engelsk - NLM (National Library of Medicine)

hospira, inc. - hetastarch (unii: 875y4127ea) (hetastarch - unii:875y4127ea) - hetastarch 6 g in 100 ml - hextend (6% hetastarch in lactated electrolyte injection) is indicated in the treatment of hypovolemia when plasma volume expansion is desired in settings where adequate alternative treatment is unavailable. it is not a substitute for blood or plasma. do not use hes products, including hextend, unless adequate alternative treatment is unavailable.

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

北京费森尤斯卡比医药有限公司 - 注射剂(大容量注射剂) - 250ml:羟乙基淀粉200/0.5 15g与氯化钠2.25g

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

北京费森尤斯卡比医药有限公司 - 注射剂(大容量注射剂) - 250ml:羟乙基淀粉200/0.5 25g与氯化钠2.25g

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

北京费森尤斯卡比医药有限公司 - 注射剂(大容量注射剂) - 500ml:羟乙基淀粉200/0.5 15g与氯化钠4.5g

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

北京费森尤斯卡比医药有限公司 - 注射剂(大容量注射剂) - 500ml:羟乙基淀粉200/0.5 30g与氯化钠4.5g

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

北京费森尤斯卡比医药有限公司 - 注射剂(大容量注射剂) - 500ml:羟乙基淀粉200/0.5 50g与氯化钠4.5g

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

华润双鹤药业股份有限公司 - 注射剂(大容量注射剂) - 500ml:羟乙基淀粉(200/0.5)30g与氯化钠4.5g

Taiwan - kinesisk - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

台灣柏朗股份有限公司 台北市松山區健康路152號9樓 (23525106) - poly(o-2- hydroxyethyl)starch (hes)(molar subs 0.42; average molecular weight 130000 da);;sodium chloride;;potassium chloride;;calcium chloride dihydrate;;magnesium chloride hexahydrate (eq to magnesium chloride 6h2o);;sodium acetate trihydrate (eq to sodium acetate 3h2o );;malic acid - 注射液劑 - sodium acetate trihydrate (eq to sodium acetate 3h2o ) (4008000670) mg; calcium chloride dihydrate (4012000350) mg; magnesium chloride hexahydrate (eq to magnesium chloride 6h2o) (4012001550) mg; potassium chloride (4012001800) mg; sodium chloride (4012002100) mg; poly(o-2- hydroxyethyl)starch (hes)(molar subs 0.42; average molecular weight 130000 da) (9600009069) mg; malic acid (9600017800) mg - blood substitutes and plasma protein fractions - 單獨使用晶質輸注液無法治療之急性出血導致之低血容積病人，本品無法取代紅血球及血漿中的凝血因子。